--- title: "Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences | EDIT Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/284268419.md" description: "Editas Medicine, Inc. announced that five abstracts have been accepted for presentation at upcoming scientific conferences, including the ASGCT 2026 Annual Meeting and the EAS Congress. The presentations will showcase new preclinical data on EDIT-401, a potential treatment for hyperlipidemia, highlighting its ability to lower LDL cholesterol through CRISPR gene editing. Key presentations include an oral presentation on the preclinical development of EDIT-401 and several poster presentations detailing pharmacokinetics and gene editing approaches. The conferences will take place from May 11 to May 27, 2026." datetime: "2026-04-27T12:31:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284268419.md) - [en](https://longbridge.com/en/news/284268419.md) - [zh-HK](https://longbridge.com/zh-HK/news/284268419.md) --- # Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences | EDIT Stock News CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead _in vivo_ development candidate, to be a transformative therapy for people living with hyperlipidemia. The complete list of Editas Medicine presentations is below. **American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15** **Oral Presentation:** **Title:** Preclinical Development of EDIT-401, a Durable _In Vivo_ CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C **Session Date and Time:** Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDT **Session Title:** Gene Therapy for Cardiovascular Diseases **Presentation Room:** 206AB **Final Abstract Number:** 380 **Poster Presentations:** **Title:** Pharmacokinetics and Pharmacodynamics of _In Vivo_ Gene Editing Therapy for Lowering LDL-C in Mice **Session Date and Time:** Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDT **Session Title:** Thursday Poster Reception **Presentation Room:** Exhibit and Poster Hall **Final Abstract Number:** 3423 **Title:** _In Vivo_ CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model **Session Date and Time:** Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDT **Session Title:** Wednesday Poster Reception **Presentation Room:** Exhibit and Poster Hall **Final Abstract Number:** 2324 **TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14** **Oral Presentation:** **Title:** Transformative LDL Cholesterol Lowering _In Vivo_ CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease **Session Date and Time:** Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDT **Session Title:** mRNA & Genome Editing: Technology & Applications **94****th** **European Atherosclerosis Society (EAS) Congress, May 24-27** **Oral Presentation:** **Title:** A Transformative _In Vivo_ CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates **Session Date and Time:** Monday, May 25, 3:45 p.m. – 5:15 p.m. EET/9:45 a.m. – 11:15 a.m. EDT **Session Title:** New Pathways for Lipid and Lipoprotein Metabolism **Presentation Room:** Nana Hall **Final Abstract Number:** 159 Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences. **About Editas Medicine** As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative _in vivo_ medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision _in vivo_ gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. Investor and Media Contacts:ir@editasmed.commedia@editasmed.com ### Related Stocks - [EDIT.US](https://longbridge.com/en/quote/EDIT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md) - [BUZZ-Editas Medicine down after $125 mln stock-and-warrants offering](https://longbridge.com/en/news/287648391.md) - [Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401](https://longbridge.com/en/news/279165482.md) - [BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 | BCTX Stock News](https://longbridge.com/en/news/287354495.md) - [Moleculin poster acceptance at ASCO shows pooled Annamycin cardiac safety across 90 patients](https://longbridge.com/en/news/287399847.md)